research interim report template

How to Write a Successful Interim Report

In many Bachelor and Masters subjects, students will commonly be required to complete an Interim Report . The University will review the Interim Report to gauge the student’s achievements to date and ensure that they are making adequate progress toward the final dissertation .

What is the Interim Report

This assignment is comprised of a written report that summarises the student’s progress on their chosen project. Students will have already completed a Project Proposal and a Project Specification, which outline the intended research, practical procedures and outcomes. The dissertation Interim Report is essentially a process of reviewing and updating these documents and noting any significant changes to your project. The Interim Report is very similar to the presentations required in ‘upgrade panels’ for PhD students, except that at the Masters level students are not expected to show progress toward a full doctoral thesis.

How do I Create a Dissertation Interim Report?

The Interim Report is usually about 20 pages in length, and it is usually submitted in the Spring of your first year of study. The typical Interim Report structure includes the following items:

Project Summary and Project Specifications

These may be the same as the documents that were submitted at the start of your degree programme. The Project Summary is a brief description of your proposed project, while the Project Specification provides a more detailed account of your intended methods and likely results. If any significant changes have been made to your project, these should be reflected in an updated Summary and Specification.

Updated Table of Contents

This may already be contained in the Project Specification Report, but if not then the Interim Report should include an up to date Table of Contents. In addition, it is helpful to include 1-2 sentences that describe the content of each chapter.

Literature Review

The Interim Report is usually accompanied by a full literature review , which will form the basis of a dissertation chapter . Like all literature reviews, it should provide an overview of the theories and practices that are most relevant to your own work. It is often organised thematically and will demonstrate the student’s ability to contextualise their project within the recent advances in their field. This will probably be the longest section of the Interim Report.

Current Progress

This section of the Dissertation Interim Report will outline what you have achieved so far. It may include mentions of the background research you’ve undertaken, skills training you’ve received, and any practical work you’ve done toward completing your project.

Obstacles to Progress

In this part of the Interim Report, students should note down any difficulties they’ve encountered so far. It should also contain some details of how the student plans to confront these challenges, whether through changes to the research plan or minor adjustments to the overall project. The University is particularly interested in this section of the Interim Report, as they want to ensure the student’s successful completion of the degree.

Planned Methodology

For most degree programmes students will also need to outline their research strategy for the remainder of the dissertation work. This may focus primarily on text-based research or it may require practical lab work. Regardless, the student should justify their chosen methodology and explain how it will adequately address the research question.

Future Project Timeline

This section details the student’s plan of action for the remainder of the degree, and is usually broken down into a month-by-month timeline. You should include all the work that is relevant to completing the dissertation, including research, project development, chapter writing and lab activities. You might also include plans for additional skill training, funding bids, and conference presentations.

Help with Writing the Dissertation Interim Report: Tips for Success

Be Specific : Be very detailed in the information that you present. Avoid generalisations and vague statements of progress. Use examples to demonstrate your progress.
Be Thorough : Be sure to mention all the work that you’ve done, even if some of it won’t be used in your final dissertation. This foundational research demonstrates your scholarly activity in the months before the Interim Report, and it also shows your ability to make discerning choices about your research project.
Be Confident : The Interim Report provides you with a useful opportunity to present your progress and refine your future actions with advice from supervisors and other faculty. However, try to avoid using a tone that makes you seem unsure of yourself or lacking confidence in your own progress. An assured and confident tone will help to convince examiners of your overall level of ability and accomplishments.
Be Criticial : Your Interim Report should demonstrate your growth as a critical, engaged scholar. This requires you to show your ability to speak about your field in a highly knowledgeable way. Furthermore, you should be able to reflect critically on your own proposed project and how it can contribute to your field. This often includes acknowledging its weaknesses or shortcomings and justifying why your approach is still a good one.

How is it Marked?

In many subject areas, Interim Reports are conducted through an oral presentation by the student. The Interim Report presentation is not marked separately, but it is taken into consideration when assessors review the written submission. In general, the marking criteria for the interim report are similar to those for the dissertation: assessors want to see error-free writing and grammar, clear structure, originality and critical thinking. Some of the marks will also be based on the quality of your progress to date – in other words, how good is the research that is described in the report?

The mark awarded for the Interim Report usually comprises a small percentage of the final dissertation module mark, typically 5% (with 90% of the mark coming from the dissertation itself and another 5% from the oral presentation of the dissertation). Marks will be awarded on the standard UK marking scale, as follows:

70 and above = First class (A) 60-69 = Second class, first division (B) 49-59 = Second class, second division (C) 40-48 = Third class (D)

This website may not work correctly because your browser is out of date. Please update your browser .

Interim reports

Interim (or progress) reports present the interim, preliminary, or initial evaluation findings.

Interim reports are scheduled according to the specific needs of your evaluation users, often halfway through the execution of a project. The interim report is necessary to let a project’s stakeholders know how an intervention is going. It provides information that will help the funders and other decision-makers determine whether to continue with the current direction, where to make adjustments if necessary, revise goals, add more resources or in the worst-case scenario, to shut it down.

An interim report is similar to a final report, in that it includes a summary, a brief description of the progress, the evaluation thus far, and an overview of the financial situation. Any delays or deviations to the plan are included and explained, as well as any comparison between actual compared to expected results.

Advice for using this method

To avoid critical issues being interpreted incorrectly, begin interim reports by stating the following:

Which data collection activities are being reported on and which are not;
When the final evaluation results will be available;
Any cautions for readers in interpreting the findings.

Advice taken from Torres et al., 2005

This detailed example of a progress report describes Oxfam's work in Haiti following a large earthquake. It is intended to account to donors, partner organizations, allies, staff, and volunteers.

"Within every picture is a hidden language that conveys a message, whether it is intended or not. This language is based on the ways people perceive and process visual information.

This book from Torres, Preskill and Piontek has been designed to support evaluators to incorporate creative techniques in the design, conduct, communication and reporting of evaluation findings.

This guide is an IDRC publication with a module dedicated to writing a research report including information on layout and design.

This guide from the University of Wisconsin Cooperative Extension, provides a range of tips and advice for planning and writing evaluation reports that are concise and free of jargon.

Davies, L. (2012). Haiti Progress Report January-December 2011 . Oxford, UK: Oxfam GB. Retrieved from https://policy-practice.oxfam.org/resources/haiti-progress-report-january-december-2011-200732/

Oxfam GB Evaluation Guidelines (accessed 2012-05-08): https://www.alnap.org/help-library/oxfam-gb-evaluation-guidelines

Stetson, Valerie. (2008). Communicating and reporting on an evaluation: Guidelines and Tools. Catholic Relief Services and American Red Cross, Baltimore and Washington, USA. Retrieved from: https://www.alnap.org/help-library/communicating-and-reporting-on-an-evaluation-guidelines-and-tools

Torres, Rosalie T., Hallie Preskill and Mary E. Piontek. (2005). Evaluation Strategies for Communicating and Reporting: Enhancing Learning in Organizations (Second Edition). University of Mexico.

USAID. (2010). Performance monitoring & evaluation tips: Constructing an evaluation report. Retrieved from: https://pdf.usaid.gov/pdf_docs/pnadw117.pdf

Expand to view all resources related to 'Interim reports'

Are you writing an evaluation report?
Evaluation reporting: A guide to help ensure use of evaluation findings
Quick tips for planning evaluation reports

'Interim reports' is referenced in:

Framework/guide.

Rainbow Framework : Develop reporting media

About Grants
Forms Directory

Research Performance Progress Report (RPPR) - Annual, Interim, and Final

The RPPR is used by recipients to submit progress reports to NIH on their grant awards. There are three types of RPPRs

Annual RPPR - Use to describe a grant’s scientific progress, identify significant changes, report on personnel, and describe plans for the subsequent budget period or year.
Interim RPPR – Use when submitting a renewal (Type 2) application. If the Type 2 is not funded, the Interim RPPR will serve as the Final RPPR for the project. If the Type 2 is funded, the Interim RPPR will serve as the annual RPPR for the final year of the previous competitive segment. The data elements collected on the Interim RPPR are the same as for the Final RPPR, including project outcomes.
Final RPPR - Use as part of the grant closeout process to submit project outcomes in addition to the information submitted on the annual RPPR. A final progress report is required for any grant that has passed its project end date and will not be extended through award of a new competitive segment.

There is no RPPR form available for download. Submit RPPR data through the eRA Commons . The links for each type of RPPR are accessed through the Commons Status tab. The Interim RPPR link will also be accessed through the Commons Status tab. It will appear one day after the project segment end date, but before it has moved to closeout. The Final RPPR link will become available through the closeout module once the grant is eligible for closeout.

NIH RPPR Instruction Guide
NIH RPPR Online Help
Final Invention Statement
Research Performance Progress Reports (RPPR) website
RPPR Help & Tutorials
RPPRs: Who Can Do What?

This page last updated on: August 22, 2024

Bookmark & Share
E-mail Updates
Privacy Notice
Accessibility
National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892
NIH... Turning Discovery Into Health

Designing the Research Proposal or Interim Report

First Online: 25 May 2023

Cite this chapter

Uche M. Mbanaso 4 ,
Lucienne Abrahams 5 &
Kennedy Chinedu Okafor 6

599 Accesses

This chapter explains what is required for postgraduate student researchers to design and submit the research proposal. In some universities, the student is required to present an interim report. It sets out the key components of the structure of the research proposal, including the research problem statement, research purpose statement, research questions or hypotheses, background to the research problem, literature review and methodology, list of references and in-text referencing. It gives specific attention to a guiding framework for thinking about originality in the research design.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save.

Get 10 units per month
Download Article/Chapter or eBook
1 Unit = 1 Article or 1 Chapter
Cancel anytime
Available as PDF
Read on any device
Instant download
Own it forever
Available as EPUB and PDF
Compact, lightweight edition
Dispatched in 3 to 5 business days
Free shipping worldwide - see info
Durable hardcover edition

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

Daoud, S., Alrabaiah, H., & Zaitoun, E. (2019). Technology for promoting academic integrity: The impact of using Turnitin on reducing plagiarism. Proceedings of the 2019 International Arab Conference on Information Technology (ACIT), United Arab Emirates , 178–181. https://doi.org/10.1109/ACIT47987.2019.8991046

Hao, J., & Ching-Chiuan, Y. (2009). PhD in design: A reflection from a PhD student and his supervisor. Proceedings of the IEEE 10th International Conference on Computer-Aided Industrial Design & Conceptual Design , China , 146–150. https://doi.org/10.1109/CAIDCD.2009.5375111

Vrbanec, T., & Meštrović, A. (2017). The struggle with academic plagiarism: Approaches based on semantic similarity. Proceedings of the 40th International Convention on Information and Communication Technology, Electronics and Microelectronics (MIPRO), Croatia , 870–875. https://doi.org/10.23919/MIPRO.2017.7973544

Download references

Author information

Authors and affiliations.

Centre for Cybersecurity Studies, Nasarawa State University, Keffi, Nigeria

Uche M. Mbanaso

LINK Centre, University of the Witwatersrand, Johannesburg, South Africa

Lucienne Abrahams

Department of Mechatronics Engineering, Federal University of Technology, Owerri, Nigeria

Kennedy Chinedu Okafor

You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

About this chapter

Mbanaso, U.M., Abrahams, L., Okafor, K.C. (2023). Designing the Research Proposal or Interim Report. In: Research Techniques for Computer Science, Information Systems and Cybersecurity. Springer, Cham. https://doi.org/10.1007/978-3-031-30031-8_3

Download citation

DOI : https://doi.org/10.1007/978-3-031-30031-8_3

Published : 25 May 2023

Publisher Name : Springer, Cham

Print ISBN : 978-3-031-30030-1

Online ISBN : 978-3-031-30031-8

eBook Packages : Engineering Engineering (R0)

Share this chapter

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Publish with us

Policies and ethics

Find a journal
Track your research

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Publications
Account settings
My Bibliography
Collections
Citation manager

Save citation to file

Email citation, add to collections.

Create a new collection
Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

Search in PubMed
Search in NLM Catalog
Add to Search

How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know

Affiliations.

1 1 Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
2 2 School of Statistics, University of Minnesota, Minneapolis, MN, USA.
PMID: 29552920
DOI: 10.1177/1740774518764449

Background: Data monitoring committees for randomized clinical trials have the responsibility of safeguarding interests of trial participants. To do so, the data monitoring committee must receive reports on safety and efficacy to assess risk/benefit and on trial conduct to ensure that the study can achieve its goals. This article outlines the key components of reports to the data monitoring committee and the important role of the unblinded statistician in preparing those reports.

Methods: Most data monitoring committee meetings include open and closed sessions. For each session, there is a report of interim results. The open session is attended by the sponsor and lead investigators, including the statistician(s) responsible for the trial design. These investigators are blinded to the interim treatment comparisons. The closed session is attended by the data monitoring committee members and by the statistician(s) who prepared the closed report. These individuals are unblinded to interim treatment comparisons and therefore are not involved in study design changes. The optimal content of data monitoring committee reports and qualifications of the unblinded statistician(s) are discussed.

Reports: Open reports should include responses to data monitoring committee recommendations, a synopsis of the protocol, a review of the protocol history and amendments, and information on enrollment, baseline characteristics, completeness of follow-up, and data quality. The open report is also a vehicle through which the sponsor and investigators should inform the data monitoring committee of relevant external information. Data in the open report are pooled over the treatment groups. The open report should not include data summaries by treatment group. The closed report should include a written summary with references to key tables and figures and methods used to prepare them. Tables and figures should summarize baseline characteristics, follow-up completeness, treatment adherence, and major safety and efficacy outcomes by treatment group. Text summaries should accompany the tables and figures. The data monitoring committee monitoring history (e.g. treatment differences at previous meetings) should be summarized. The unblinded statistician preparing the closed report should be familiar with the protocol and data collection plan and be capable of customizing the report to the current stage of the trial. This includes anticipating questions that may arise during the data monitoring committee review and pro-actively including data summaries to address these questions.

Conclusions: There is considerable variation in the quality of open and closed data monitoring committee reports. Open and closed data monitoring committee reports should be concise, up to date, and informative. To achieve this, unblinded statisticians responsible for preparing closed data monitoring committee reports should be familiar with the statistical methods, the trial protocol, and the data collection plan. They should be capable of anticipating questions from the data monitoring committee and responding to requests for additional analyses.

Keywords: Data monitoring committee; closed report; open report; unblinded statistician.

PubMed Disclaimer

LinkOut - more resources

Full text sources, other literature sources.

scite Smart Citations

Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

U of T Home
Faculty Home

Engineering Communication Program

Progress / Interim Reports

Progress reports are common in engineering. As the name suggests, they document ongoing projects. They might be one-page memos or long, formal documents. Such a report is aimed at whoever assigned the project. Its goal is to enable the manager or sponsor of a project to make informed decisions about the future of the project. Usually, progress reports are stressful. The sponsor wants a job done quickly and cheaply; the engineer needs to ensure accuracy and quality. A sponsor might cancel even a quality job if it is behind or over budget. As the engineer, you need to please the sponsor and do the job well. Yet, any project of size or significance is bound to encounter snags: additional requirements, miscommunications, problems, delays, or unexpected expenses. A progress report must account for those snags.

The original proposal for the project determines the structure: make use of original milestones or the timeline. With this in mind, the simplest structure is as follows:

Introduction
Work Completed
Work Scheduled

But a more comprehensive list of components will give you a clearer structure, even if you return to the simpler structure for the report itself. Beer and McMurrey’s [1] Detailed Structure:

Project Description
Progress Summary
Problems Encountered
Changes in Requirements
Overall Assessment of the Project
(This document adds:) Report Apparatus (titles, references, etc.)

1. Introduction: As always, first indicate the purpose of the report and its intended audience. Clearly define the time period covered in the report (see also titles). Then, explain the project’s objectives and summarize the major issues. Sometimes the summary can be a separate section from the introduction [2].

2. Project Description: In very short reports, the introduction might contain this section, but if it is under its own heading, readers who are familiar with the project can skip it. Someone unfamiliar with the project, however, needs summarized details such as purpose and scope of the project, start and completion dates, and names of parties involved [1]. Often this section can be adapted from a proposal or borrowed from a previous progress report.

3. Progress Summary: This is the substance of the report (so “summary” may be a misnomer). You want to discuss work done, work in progress, and work to be done. You might just use these as subheadings to structure the section. This would be a project-tasks approach. Other approaches are time-periods or a combined approach.

Project-tasks approach: Focus on the tasks. Defined milestones can logically organize your discussion into this kind of structure. Also if you are working on a number of semi-independent tasks at the same time, this approach will work well [1].
Time-periods approach: Focus on time: the previous period, the current period, the future. If a timeline (or deadline) is more important than milestones, then use this approach. Also, use it for projects with a simple linear structure.
Combined approach: The two above approaches could be combined if, for example, under previous work, you break down what you have done by individual tasks. Or, under the tasks, you focus on what part is complete, what part is in progress, and what part is yet to come.

Your project (and sometimes your sponsor) will determine which of these three you use. If the problems encountered or changes required are time-related, then use the time-periods approach to your advantage; likewise, if the problems or changes relate to specific tasks then use the project-tasks approach. Another item that may be included here is a summary of financial data. This last item could be contained in a table or appendix, or an independent section.

4. Problems Encountered: As noted in the opening, snags are expected. Don’t hide from them; explain what they are and how they might affect key areas of the job (such as timing, price or quality). If the problem occurred in the past, you can explain how you overcame it. This is least serious; in fact, you look good. If the problem is in front of you (now or in the future), explain how you hope to overcome it, if you can.

5. Changes in Requirements: Here, you record the changes to the project: milestones added, new requirements, or schedule changes (good or bad). Even if these changes have not affected the ultimate goal of the project, you need to tell the sponsor how problems have been accommodated. Note: If changes are a direct result of problems encountered, sections 4 and 5 may be combined. This would lead to a modified organization: first problem and the change it required, then the next problem and change, and so on.

6. Overall Assessment of the Project: Since a progress report is not about a finished work, the conclusion needs only to give your professional opinion of how the project is going. Being unrealistically optimistic is as inappropriate as being unduly negative. Beware of promising early completion: a single setback can gobble up much time. Likewise, don’t overreact if you are behind schedule. You may also gain time along the way. Far more significant for the engineer is to explain anything that may change the expected quality of the final product. Keeping in mind your purpose can help you focus here: your goal is to enable the manager or sponsor to make informed decisions.

7. Report Apparatus: A long progress report will include all the apparatus of formal reports: letter of transmittal, title page, table of contents, abstract, appendices, references. Only the most common will be addressed here.

Title: whether on a separate page or merely as a header, the title sends an important message to the reader. It needs to be clear and concise. Sample good title:

PROGRESS REPORT: Manufacturing Custom Relief Valve Assemblies XYZ Company

Reporting Period: April – July 1997

Subtitle: Note that the subtitle in the above example incorporates the dates covered by the report. This makes handy reference for a reader, particularly on a large project where more than one progress report may be necessary.

Appendices: In a short report (less than 10 pages) keep appendices to a minimum. It is always appropriate, however, to lodge financial data in an appendix if it does not fit elsewhere in the report. An important guideline is that it is only worth including an appendix if you mention it in the guts of the report. Otherwise, leave it out altogether.

References: Systems of referencing vary widely within engineering disciplines. (See Online Handbook / Accurate Documentation for information about two of these systems (IEEE and Author-Date) and a Bibliography Builder, which formats bibliography entries automatically for you)

[1] Beer, D. and McMurrey, D. A Guide to Writing as an Engineer. Toronto: Wiley, 1997. [2] Markel, M. and Holmes, H. Technical Writing: Situations and Strategies. Scarborough: Nelson Canada, 1994.

Accessibility
Student Data Practices
Website Feedback

#InvestInHumanity

Search form

Cerf interim reporting template.

Guides and Templates

On this page you will find PEP guides and/or templates for each stage of the research cycle—from project proposal to dissemination of findings and recommendations—as well as PEP's institutional policies.

Grants Manual

Non-experimental research projects.

PEP standard grants manual for non-experimental research projects. Updated October 2021

Experimental Research intitiatives

Fostering Autonomous Local Impact Evaluations for Policymaking : FALIEP Grants Manual updated March 2022

Strengthening Impact Evaluation Capacities for Development : SIECD Grants Manual updated March 2022

Impact Evaluation Government Mentoring Program : IE Mentoring Grants Manual updated June 2019

Templates & Guides

Grant application.

NON-EXPERIMENTAL RESEARCH PROJECTS: Proposal template and Proposal guidelines

EXPERIMENTAL RESEARCH PROJECTS:

Using a Randomized Controlled Trial (RCT) : Template and Guidelines to prepare an Expression of Interest (EOI)
Using a Field Experiment: Template and Guidelines to preparing a proposal
Guide for team leaders of PEP-supported research projects
Guide for how to submit a revised research proposal

Pre-analysis Plan

Pre-analysis Plan for Experimental Research projects (Word file). Updated in 2021

Interim Reports

NON-EXPERIMENTAL PROJECTS:

Content : Interim reports should include the results for all of the analysis planned in the accepted proposal.
Format : Please use the Final Report/Working Paper template relevant to your research method (see below).
Goal : The goal is to prove that your project is progressing satisfactorily and that it can be reasonably assumed that your team will be able to prepare a final report in time for presentation at the next PEP annual conference.

EXPERIMENTAL PROJECTS (RCTs, Field experiments):

Interim Research Report #1 refers to an updated version of the Pre-analysis Plan including an analysis of baseline data.
Interim Research Report #2 refers to an updated version of the Interim Research Report #1 including an update on the progress of the intervention.
Format : Please update your existing Pre-analysis Plan based on the template (see above). This template contains specific sections to be filled at each Interim Report instance.

Submission guide (all)

Final Report and Working Paper

For CGE Modeling projects: Template (.doc)

For Experimental Research projects: Template (.doc)

For Microeconomic Analysis projects: Word template (.doc) and Overleaf/LaTex template (zipped file)

N.B. Teams wishing to work in Overleaf should contact with their mentor who will invite them to an Overleaf project

Make sure to include the correct acknowledgement . Refer to section A3 of your Research Support Grant Agreement beginning:

“ This work was carried out with financial and scientific support from the Partnership for Economic Policy (PEP) ”.

Submission guide

Dofile Templates (Experimental)

ONLY FOR EXPERIMENTAL RESEARCH PROJECTS:

Submission requirements for dofiles and databases Data package requirement matrix (docx) Glossary template - Comments (docx) Dofile template header (zipped file)
Distance buffer randomization User manual (docx) Distance buffer for randomization (Dofile, zipped file) Example data (dta, zipped file)
Pairwise matching User manual (docx) In Pursuit of Balance - Working Paper (pdf) Pairwise matching and example (Dofiles, zipped file) Example dta file (zipped file)
Re-randomization for balance in small samples Big stick rerandomization - User manual (docx) Big Stick Do Files (clean) (zipped file) Example Dataset Files (Dofile, dta files, zipped file)
Baseline balance check User manual (docx) Baseline Balance Do File (clean) (zipped file) Example Data Baseline Balance (xls, dta, Dofile, zipped file)
Regression analysis and output User manual (docx) Regression Analysis (Dofile, clean) (zipped file) Examples (dta, Dofile, txt, xml, zipped file)
Multiple Hypothesis Testing User manual (docx) Database (dta file, zipped) Example dofile (zipped)

Policy engagement, outputs & dissemination

Stakeholder matrix and engagement strategy

Policy influence - objectives and strategy

Policy Paper template (and instructions)

Policy Brief guidelines

Dissemination Strategy template

Technical Reports

Fill in online in your PEP project's intranet space.

See the tutorial

Slide Presentation

Proposal presentation template

Use of this template is mandatory for applicants invited to present a proposal during a PEP annual conference
See also guidelines for presenting a research proposal at a PEP annual conference

Final Report or Working Paper presentation

Use of this template is mandatory when presenting PEP research results at a PEP annual conference or study visit.
See also guidelines for presenting a final report at a PEP annual conference

Generic external event presentation template

Use of this template is mandatory i f your participation is funded by PEP.
For National Policy Conferences and International Conferences , please see specific sections below.

Study Visit

Application for study visits

National Policy Conference

Application for National Policy Conference grants

Guidelines for submitting a National Policy Conference grant application

Please download and use the PPT template and logos package for your research program:

Climate Change in sub-Saharan Africa (2020-23)
Covid-19 Responses for Equity (CORE) (2020-22)
What works for youth employment in Africa (2021-24)
Barriers to decent work for women (Co-Impact) (2022-23)
Social gender norms and women's resilience under income shocks (2022-23)

International Conferences

Participation grant

In-person event application

Online event application

External event presentation template Use of this template is mandatory i f your participation is funded by PEP.

Grouped PEP logo

Horizontal PEP logo

Journal Publications

Publication Strategy for Experimental Research projects (Word file). Updated in 2021

PEP journal classification (for journal publication grants)

See also: Guidance on publishing and communicating research

How to write a professional biography for your PEP profile: Guide

How to incorporate a Gender Perspective into Economic Research: Article

For guidance on publishing and communicating research , please review that section of the PEP website.

Institutional policies

Acknowledgement texts

Conflict of Interest Policy

Intellectual Property Statement

Open Access and Data Policy

Penalty Policy

Interim Reports

You may be required to produce an interim report as part of a larger project, such as your final Individual Project. This report serves an important purpose in setting out what you are hoping to achieve and how far you have got in achieving this.

The reader is looking to answer questions, such as:

What is the student trying to achieve? Is this reasonable with the time and resources available?
What is the context of this project? Why is the research needed? What other research is it building on?
Is the student's work convincing? Have claims been supported by evidence from literature? Does the student demonstrate good knowledge of the field by having broad, relevant and up-to-date sources?
Does the student show attention to detail in the accuracy of calculations and writing?
Is it clear what the student has done, needs to do, and what the steps to complete the project are?

Interim report requirements

Although the interim report is significantly shorter than the final report, it should not be vague. It should provide detailed information that is relevant to the purpose of an interim report.

Broad and up-to-date understanding of the literature

“Your literature review is too brief. You need to demonstrate evidence of further reading and greater technical understanding of the field”. (Tutor feedback)

Although your interim report won’t contain your full literature review, it should show depth and breadth. The reader will want to be able to see you understand the field.

Progress to date and next steps

“Lacks detail of progress to date.” (Tutor feedback)

You need to show the reader what you have achieved and how you plan to complete the project. Be specific so that the reader can assess whether your progress and plan are reasonable.

Attention to detail

“Referencing was variable throughout the report. This reduces the professionalism of the report and makes it look as though it hasn’t been written with care and attention, contradicting the general standard of the report.” (Tutor feedback)

Although the interim report is not the final report, it is not a draft. It may be assessed in its own right. This means that you need to pay attention to detail and dedicate time to producing it.

Relevance of literature to your project

“The literature review could have been improved by explicitly pointing to how this information is used in the project. It was often difficult to understand how the information in the report related to your work.” (Tutor feedback)

Your interim report, like other reports and essays, needs to connect the literature clearly to your project. The danger when writing a literature review is that it contains a series of paraphrases or summaries, but lacks the analysis that develops the argument to show why this is relevant to your project.

Your interim report should:

State your aims and objectives.
Explain your research.
Show what you have achieved.
Demonstrate the steps to complete the project on time.

Other University of Southampton sites

English Support Classes

Useful Downloads

Example MSc Interim Report

It is important to focus on the story of the research and link each section. Reading the report it can be difficult to determine the relevance of the sections to the overall story. This makes it feel disjointed and it can be difficult to determine the problem that needs to be solved, what others have done before, and what you plan to do that will help solve it.

University of Lincoln Computer Science Interim Report Template

A suitable template that can be used for the interim report submission for Computer Science at the University of Lincoln. Relevant as of 2022-23.

Get in touch

Have you checked our knowledge base ?

Message sent! Our team will review it and reply by email.

Email:

WuXi Biologics

Offering End-to-End Solutions

Vision & Mission
History & Awards
Business Ethics
Scientific Advisory Board
Locations & Facilities

$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.

$A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.

Mammalian-Derived Product Services

A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.

Product types we support:

$Discover information about the various drug development services we provide for this product type

Monoclonal Antibodies

Discover information about the various drug development services we provide for this product type

Bispecific & Multispecific Antibodies

Fc-Fusion Proteins

Antibody Fragments

Recombinant Proteins / Enzymes / Cytokines

Non-Vaccine Viral Products

Antibody Drug Conjugates (ADCs)

Virus-Like Particles (VLPs)

Subsidiaries

$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.

$High quality, expert services for biologics produced from microbial fermentation.

Microbial-Derived Product Services

High quality, expert services for biologics produced from microbial fermentation.

Product types we support

Enzymes / Cytokines

Plasmid DNA (pDNA)

$Integrated Discovery Platform From Concept to IND

$Industry-leading expertise, state-of-the-art facilities, and multiple antibody generation technology platforms for the discovery of novel monoclonal, bispecific and multispecific antibodies, immunocytokines and other biologics.

Integrated Discovery Service

Industry-leading expertise, state-of-the-art facilities, and multiple antibody generation technology platforms for the discovery of novel monoclonal, bispecific and multispecific antibodies, immunocytokines and other biologics.

$Specializing in monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and other biologics, we offer our customers high productivity and high quality antibody and protein production services for all of your research needs.

Protein Sciences

Specializing in monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and other biologics, we offer our customers high productivity and high quality antibody and protein production services for all of your research needs.

$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.

$We unite expert protein engineering capabilities with our high throughput and high productivity research-scale protein production services to enable all of your R&D initiatives.

We unite expert protein engineering capabilities with our high throughput and high productivity research-scale protein production services to enable all of your R&D initiatives.

$Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.

Cell Line Engineering

Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.

$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.

Analytical Sciences

Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.

$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.

Process Development & Scale Up

Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.

$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.

Formulation & Drug Product Development

We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.

$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.

Cell Banking & Characterization

Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.

$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.

Viral Clearance

Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.

$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.

Regulatory Support

Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.

$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.

$Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.

Clinical DS GMP Manufacturing

Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.

$Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.

Clinical DP GMP Manufacturing

Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.

$We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.

Commercial DS GMP Manufacturing

We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.

$Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.

Commercial DP GMP Manufacturing

Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.

$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.

$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.

Biosafety Testing

High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.

$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.

Analytical Testing

We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.

$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.

Centers of Excellence (CoE)

Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.

$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

Global Quality Control (QC)

Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).

$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.

$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.

Global Compliance

Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.

$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.

Quality Assurance

Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.

Quality Control

$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.

Regulatory Affairs

Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.

$Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.

$Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.

Target to Lead

Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.

$Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.

Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.

$Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.

Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.

$A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.

$The WuXiBody™ platform for the generation of bispecific (bsAb) and multispecific (msAb) antibodies speeds up drug development by 6-18 months, cuts production costs, and enables flexible assembly of mAb sequence pairs into various formats with different valency.

Bispecific & Multispecific Antibodies - WuXiBody™

The WuXiBody™ platform for the generation of bispecific (bsAb) and multispecific (msAb) antibodies speeds up drug development by 6-18 months, cuts production costs, and enables flexible assembly of mAb sequence pairs into various formats with different valency.

$Using advanced technologies to generate diverse monoclonal antibodies (mAb) for various targets. Our experienced scientists overcome technical challenges to deliver high-quality mAbs to our clients worldwide.

Advanced Hybridoma Platform - WuXiHybrid™

Using advanced technologies to generate diverse monoclonal antibodies (mAb) for various targets. Our experienced scientists overcome technical challenges to deliver high-quality mAbs to our clients worldwide.

$Offering high-quality phage display library construction and customized library selection and screening services via our WuXiLiAb® human naïve / synthetic phage display libraries, VHH naïve / humanized VHH synthetic libraries and antibody immune libraries.

Naive Phage Display Library - WuXiLiAb™

Offering high-quality phage display library construction and customized library selection and screening services via our WuXiLiAb® human naïve / synthetic phage display libraries, VHH naïve / humanized VHH synthetic libraries and antibody immune libraries.

$Novel technology platform to enable the development of multispecific proteins. Highly flexible platform capable of generating multispecific antibody and protein therapeutics with high affinity, low immunogenicity risk and excellent developability characteristics.

VHH-based Multispecific Antibody Platform - SDARBody™

Novel technology platform to enable the development of multispecific proteins. Highly flexible platform capable of generating multispecific antibody and protein therapeutics with high affinity, low immunogenicity risk and excellent developability characteristics.

$An innovative scFv (single-chain fragment variables)-based platform for the generation of bispecific or multispecific antibodies from nearly any sequence pair. The platform significantly improves scFv stability providing bsAbs and msAbs with strong developability characteristics.

ScFv-based BsAb & MsAb Antibody Platform - SKYBody™

An innovative scFv (single-chain fragment variables)-based platform for the generation of bispecific or multispecific antibodies from nearly any sequence pair. The platform significantly improves scFv stability providing bsAbs and msAbs with strong developability characteristics.

$An advanced, high speed, high throughput and high resolution antibody screening strategy using Beacon® technology for the rapid discovery of monoclonal antibodies (mAb) from any host species.

VAST-B Single B-Cell Antibody Discovery Platform

An advanced, high speed, high throughput and high resolution antibody screening strategy using Beacon® technology for the rapid discovery of monoclonal antibodies (mAb) from any host species.

$Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.

$Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.

Ultra-Intensified Fed-batch platform - WuXiUI™

Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.

$Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.

Rapid Research Material Generation - WuXian™

Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.

$Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.

Cell Line Development - WuXia™

Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.

$This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.

Continuous Bioprocessing - WuXiUP™

This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.

$Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.

ADC Development Platform - WuXiDAR4™

Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.

$Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.

High Concentration & HTP DP Platform - WuXiHigh™

Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.

$Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.

$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.

Single-Use Bioreactors

We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.

$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.

Scale-Out Biomanufacturing

Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.

$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.

Robotic Aseptic Filling

Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.

$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.

Continuous Manufacturing Process

Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.

Environmental
ESG Latest News
Experienced Professionals
Employee Stories Worldwide
Job Opportunity
Talent Pool
Corporate Governance
Financial Reports
Announcements & Circulars
Stock Information
Presentations & Webcasts
Investor Day
Investors Contact

Press Releases

Knowledge Center

Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7% Added 61 new integrated projects, including 4 from late-phase and commercial stage Client’s molecule recently acquired by MNC, highlighting a potential best-in-class CD3 asset utilizing three of our proprietary technology platforms Total integrated projects of 742, one of the largest portfolios of complex biologics Successful EMA inspections of 13 products and FDA inspections of 2 products in 1H24

Hong Kong, August 21, 2024 – WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 (“Reporting Period”).

Financial Highlights

Revenue : The Group’s revenue for the Reporting Period matches that of the first half of 2023, totaling RMB 8,574.2 million, with a year-on-year (YoY) increase of 1.0%. Excluding the COVID sales in the same period last year, the non-COVID revenue grew by 7.7%, and the non-COVID late-phase & commercial manufacturing revenue grew by 11.7% YoY. Key drivers supporting our base revenue growth include: (i) the successful execution of the Group’s “Follow and Win the Molecule” strategies, combined with our leading technology platforms, best-in-industry timeline and excellent execution track records; (ii) an expanded spectrum of services offered to the biologics industry, including fast-growing technology platforms such as antibody-drug conjugates (ADCs) and bispecific & multi-specifics; (iii) robust growth in pre-IND revenue, which more than offset the impact of significant Discovery Services deals in 1H 2023; and (iv) the utilization of newly expanded capacities, including the ramp-up of manufacturing sites in Europe and the U.S.
Gross Profit and Gross Profit Margin : IFRS gross profit was RMB3,350.0 million compared to RMB3,560.6 million in the same period last year. Adjusted gross profit was RMB3,811.2 million compared to RMB3,993.1 million in the same period last year. IFRS gross profit margin was 39.1% and adjusted gross profit margin was 44.4%. The decrease of gross profit margin was mainly due to the margin mix impact from the significant Discovery Services deals in 1H 2023, the slightly lower capacity utilization in China due to the COVID volume in the same period last year, the continued impact of the ramp-up of new manufacturing facilities in Ireland, Germany, and the U.S., all of which were partially offset by the efficiencies achieved from the WBS and other continuous improvement initiatives.
EBITDA and EBITDA Margin : EBITDA was RMB2,805.9 million compared to RMB3,230.6 million in the same period last year. Adjusted EBITDA was RMB3,570.4 million compared to RMB3,818.3 million in the same period last year. EBITDA margin was 32.7% and adjusted EBITDA margin was 41.6%.
Net Profit and Net Profit Attributable to Owners of the Company : IFRS net profit and net profit attributable to owners of the Company was RMB1,780.3 million and RMB1,499.1 million, respectively, representing a YoY decline of 23.9% and 33.9%. The decline was due to, among other factors, (i) an increase in selling, marketing and administrative expenses (“SG&A”) as the Group continues to invest in its geographic footprint, (ii) an increase in SG&A for WuXi XDC Cayman Inc., a non-wholly owned subsidiary of the Company, as a standalone listed company on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 2268), and (iii) an unmaterialized foreign exchange translation loss as a result of the depreciation of Euro against RMB year-to-date.
Adjusted Net Profit : Adjusted net profit was RMB2,544.8 million, down 13.0% YoY from a record-high base in 1H 2023.
Basic earnings per share (EPS) : Basic EPS and adjusted basic EPS were RMB0.37 and RMB0.55, respectively.

Business Highlights

Amid a dynamic geopolitical landscape, the Group added 61 new integrated projects in 1H 2024, demonstrating the Company’s resilience and its ability to maintain growth. This, compared to 46 new projects added in 1H 2023, is one of our best 6-month periods for new project adds to date. Among the 61 newly added projects, 52 were from pre-IND, 5 from early-phase, 3 from late-phase, and 1 was from the commercial manufacturing phase. We believe that our robust business activities in the pre-IND stage signal early signs of a biotech funding recovery. During the Reporting Period, the Group continued to execute its “Win-the-Molecule” strategy, adding 9 post-IND projects, among which 4 are in the late-phase and commercial manufacturing stages. Since 2018, the Group has won 78 projects under the “Win-the-Molecule” initiative, with the winning formula centered on quality, speed, and advanced technological platforms.
The number of late-phase projects increased to 56, laying a strong foundation for future commercial manufacturing. The number of commercial manufacturing projects was 16, as we removed 8 COVID and 1 non-COVID dormant projects. The total number of integrated projects was 742, representing one of the largest portfolios of complex biologics, including bispecifics & multispecifics (123), ADCs (167), fusion proteins (76) and vaccines (23). Among the 123 bispecifics & multispecifics projects, WuXiBody TM and SDArBody TM accounted for nearly half, as both proprietary platforms continue to gain worldwide recognition.
As of June 30, 2024, total backlog reached US$20.1 billion, the same level as the first half of last year, including US$13.0 billion service backlog and US$7.1 billion upcoming potential milestone backlog. Backlog within 3 years exceeded US$3.6 billion, providing high visibility for near-term revenue opportunities.
The Group offers end-to-end CRDMO services through our global network. Our Ireland site is making great progress overall and is seeing significant commercial manufacturing demands from 2024 and onwards, with 2025 almost fully booked. MFG6.1 successfully completed its first PPQ campaign in 1H 2024, and MFG6.2 expansion is on track to be completed in the 4Q of 2024. MFG7 commenced commercial manufacturing, though there has been a slight delay in the ramp-up due to an operational issue during an engineering run. The site remains on track to reach its steady-state in 2026, serving a critical role in our “Global Dual Sourcing” network. For our Singapore site, construction work has commenced, initially to support XDC’s operation readiness in 2026. Design-work for WuXi Biologics facilities is still ongoing.
The Group’s unified and consistent quality system has been pivotal in driving our clients’ success and remains one of our key competitive advantages. A total of 21 inspections from the EMA and FDA were completed, with a 100% success rate in passing pre-approval inspections (PAIs). In 1Q 2024, EMA inspection of 13 products was successfully completed. In 2Q 2024, FDA inspection of 2 products was successfully completed.
Our industry-leading technology platforms span from discovery to development and manufacturing. Examples of discovery technologies include WuXiBody TM (for Bi-/Multi-specific antibody), T cell engager (TCE) platform, tumor associated antigens (TAA) mAb discovery, and single B cell technology. Examples of development technologies include WuXia TM (cell line development), WuXiDAR4 TM (drug antibody ratio technology), and WuXiHigh TM (customized formulation strategies for high concentration drug products). Examples of manufacturing technologies include WuXiUI TM (ultra-intensified fed-batch manufacturing) and WuXiUP TM (ultra-high productivity continuous processing). WuXiUI TM is our next-gen manufacturing process that can increase titer by 3-6x with culture time comparable to traditional fed-batch processes, and is currently undergoing pilot runs. WuXiUP TM can increase titer by 5-15x, and resolve various quality issues, making it an ideal technology for unstable molecules, molecules that clients wish to increase titer of significantly, or molecules experiencing quality issues. Recently, our client, Curon Biopharmaceutical’s investigational B-cell depletion therapy CN201 was acquired by Merck & Co., Inc. CN201 utilizes 3 aforementioned proprietary technology platforms: WuXiBody TM , TCE platform and WuXiUP TM .
Our people are key assets of WuXi Biologics. As of June 30, 2024, the Group’s total staff comprised 12,435 employees, including approximately 4,200 scientists, and the total retention rate was approximately 94%. During 1H 2024, we announced the planned retirements of Dr. Weichang Zhou (former CTO), Mr. Peter Shen (CMO), and Dr. Jerry Xu (former CQO). We deeply appreciate their contributions to WuXi Biologics. The transition was seamless, with Dr. Sherry Gu (CTO), Dr. Wei Guo (Head of Global Manufacturing, effective August 2024), and Mr. Ing Hou Loh (Head of Global Quality) assuming these roles. With a deep bench of industry veterans who possess extensive domain expertise and proven leadership records, the Group is well-positioned to continue building a strong and sustainable organization for many decades to come.
WBS (WuXi Biologics Business System) is our lean operation and management system launched in 2021. During 1H 2024, by implementing approximately 60 Kaizen projects and events, the Group delivered Gross Profit Margin enhancement of roughly 100 basis points, along with significant business growth, inventory reduction, labor hour savings, and quality improvements to combat operation headwinds. Additionally, ESG Kaizen projects contributed to the Group’s ESG initiatives by achieving remarkable carbon emission reduction, material savings, waste reductions and more recycling, and water savings. We will continue to promote WBS as our lean culture to drive continuous improvements across all facets of our operations, to create better value for our clients, employees and partners.
The Group has incorporated ESG as an essential part of its sustainable growth strategy. The Group’s ESG performance has been widely recognized by the industry and has been awarded an AAA rating from MSCI ESG Ratings, a Platinum Medal from EcoVadis, and was named an ESG Industry Top-Rated Company and an APAC Regional Top-Rated Company by Sustainalytics. In 2024, WuXi Biologics was included in S&P Global’s Sustainability Yearbook 2024 with a Top 1% S&P Global Corporate Sustainability Assessment (CSA) ranking and was named an Industry Mover.
The Group has always been committed to serving and contributing to the global healthcare community while adhering to the highest standards of regulatory compliance and operational excellence. The Group noted the introduction of the BIOSECURE Act in the U.S. Congress and subsequent amendments to it, including a proposed “grandfather” clause with transition period. The contents of the draft legislation remain subject to further review and modification as it moves through the legislative process and the legislative route also involves uncertainty. As a global biologics CRDMO platform, the Group does not have a human genomics business, nor does it collect human genomic data in any of its businesses around the world. The Group firmly believes that it has not, does not, and will not pose a security risk to the United States or any other countries. The Group will continue to closely monitor this process and remains committed to supporting its clients globally and to operating in accordance with the applicable laws and regulations of all jurisdictions where it has business operations.

Management Comment

Dr. Chris Chen, CEO of WuXi Biologics, stated, “Amid a dynamic macroeconomic and geopolitical environment, our business has demonstrated strong resilience. This is attributed to our unique CRDMO business model which we believe is the most efficient for our industry, as well as the successful implementation of our ‘Follow and Win the Molecule’ strategies. In the first half of 2024, we added 61 new integrated projects, including 4 from late-phase and commercial stages. This is a strong testament to our clients’ endorsement of our exceptional execution and our technological leadership. Our client Curon’s molecule was recently acquired by Merck & Co., Inc., highlighting a potential best-in-class CD3 asset (CN201), which was discovered, developed, and manufactured using 3 of our proprietary technology platforms, WuXiBody TM , TCE platform and WuXiUP TM .”

Dr. Chris Chen added, “Our business fundamentals remain strong. The Company’s unified and consistent quality systems, proprietary technology platforms, global talent pool – led by a seasoned management team and includes a strong technical team with over 4,200 scientists – and exceptional execution distinguish WuXi Biologics in our industry. We remain firmly committed to serving our global clients in the healthcare community and benefiting patients worldwide.”

Dr. Ge Li, Chairman of WuXi Biologics , concluded, “WuXi Biologics delivered solid business performance in the first half of 2024 despite an uncertain external environment and challenging comparisons year over year. Looking ahead, we will continue to adhere to our end-to-end CRDMO business model, expand our global presence and further improve our execution. We will continue to enhance our R&D and manufacturing efficiencies, deliver superior value to our partners, and benefit patients worldwide as an end-to-end, one-stop service provider for the biopharmaceutical industry. We remain dedicated to delivering groundbreaking therapies to patients and fulfilling our vision that ‘every drug can be made and every disease can be treated’.”

Key Financial Ratios (For the Six Months Ended June 30)


Revenue (In RMB million)	8,574.2	8,492.0	1.0%
Gross Profit (In RMB million)	3,350.0	3,560.6	(5.9%)
Net Profit (In RMB million)	1,780.3	2,337.9	(23.9%)
Net Profit Attributable to Owners of the Company (In RMB million)	1,499.1	2,266.7	(33.9%)
Adjusted Net Profit (In RMB million)	2,544.8	2,925.6	(13.0%)
EBITDA (In RMB million)	2,805.9	3,230.6	(13.1%)
Adjusted EBITDA (In RMB million)	3,570.4	3,818.3	(6.5%)
Adjusted Diluted EPS (In RMB)	0.52	0.65	(20.0%)

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding 8 COVID CMO projects and 1 non-COVID dormant CMO project).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Forward-Looking Statements

This announcement may contain certain “forward-looking statements” that are not historical facts, but instead are predictions about future events based on our expectations as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this announcement speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Non-IFRS Measures

To supplement the Group’s condensed consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS.

The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s core business. These non-IFRS financial measures, as the management of the Group believes, is widely accepted and adopted in the industry in which the Group is operating in. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. Shareholders of the Company and potential investors should not view the adjusted results on a stand-alone basis or as a substitute for results under IFRS. And these non-IFRS financial measures may not be comparable to similarly-titled measures represented by other companies.

[email protected]

IMAGES

7+ Research Report Templates
Interim Report Template
Interim report
Interim Progress Report Sample
Research Report Presentation
Readiness and preparatory support interim progress report template

COMMENTS

PDF Interim Report Template
If an interim analysis is scheduled, summary of outcome data by treatment group. Summary of publications/finding since the last DSMB meeting. Any major scientific, protocol related, or safety updates since the last DSMB. Summary of the data completeness (e.g., percentage of missing data). Assessment of participant adherence to the treatment ...
How to Write a Successful Interim Report
Be Confident: The Interim Report provides you with a useful opportunity to present your progress and refine your future actions with advice from supervisors and other faculty. However, try to avoid using a tone that makes you seem unsure of yourself or lacking confidence in your own progress. An assured and confident tone will help to convince ...
PDF Interim Reporting Template
Project Name. Re-Engineering Assessment Practices [REAP] in Higher Education, University of Strathclyde. Report compiled by. David Nicol and Catherine Owen. With contributions from. Gillian Roberts, Linda Creanor, Steve Draper. Reporting period. Second Interim Report 1st February 2006 - 31st July 2006. Section One: Summary.
Interim reports
Interim reports. Interim (or progress) reports present the interim, preliminary, or initial evaluation findings. Interim reports are scheduled according to the specific needs of your evaluation users, often halfway through the execution of a project. The interim report is necessary to let a project's stakeholders know how an intervention is ...
Research Performance Progress Report (RPPR)
The RPPR is used by recipients to submit progress reports to NIH on their grant awards. There are three types of RPPRs. Annual RPPR - Use to describe a grant's scientific progress, identify significant changes, report on personnel, and describe plans for the subsequent budget period or year.; Interim RPPR - Use when submitting a renewal (Type 2) application.
PDF Prepare & Submit Your Annual, Final and Interim Project Reports
9. You will shift to the Changes/Problems tab. Fill out all required information and click Save/Next Section to continue. To complete the tab, you must either fill out all required text boxes or click Nothing to Report. Within the Changes/Problems tab, describe any changes or problems that occurred on the project during the reporting period.
PDF Interim Progress Report Template
Interim Progress Report Template Use this template to complete PCORI interim progress report requirements. Limit Scientific Report to 5 pages. Limit Non-Technical Report to 2 pages. Date (mm/dd/yyyy): PCORI Project Title: ... Describe the plan to disseminate the funded research. Include any potential facilitators and/or barriers to dissemination.
PDF Sample Interim Report
You may use this document as a template to prepare your responses. ... Sample Interim Report - 1 - REPORT INFORMATION Due On: [displays due date of report] ... This can include Project Narratives, Outputs, Research and/or other grant-specific information to demonstrate progress. Budget, with expenditures - for the current budget period. Please ...
PDF Larger Research Grant (LRG) Interim Report
FINANCIAL REPORT . Please complete the separate Excel budget file sent with this template. The financial report should include actual expenditure for the period in question, and planned expenditures for the next reporting period. Deviations of more or less than 20% from the budget in the contract should be explained in the "Cost Notes" section.
Designing the Research Proposal or Interim Report
A research proposal is a coherent document presenting (i) a very short introduction, (ii) the research problem statement and purpose statement and (iii) the research questions. It includes (iv) a background discussion, (v) a literature review and analytical framework and (vi) a methodological discussion (Figure 3.2 ).
Research Performance Progress Report (RPPR)
Federal Register Notice Announcing the Format For Use in Submission of Interim and Final Research Performance Progress Reports. Interim Research Performance Progress Reports. Agency Interim RPPR Implementation Plans. DHHS/NIH (and Other PHS Agencies) January 2012. DHS.
PDF Format for Use in Submission of Interim and Final Research Performance
interagency research, it is important for Federal agencies to manage awards in a similar fashion. The RPPR is to be used by agenci. that support research and research-related activities for use in submission of progress re. rts. It is intended to replace other performance reporting formats currently in use by ag.
PDF Report Sample Heckscher Foundation Interim Report Instructi
logic model.The response for each is limite. to 75 words.Financial Report: This report provides an up-to-date, clear accounting of actual expenses for which Heckscher grant dollars were used and is based on the project budget you submitted with your gran. Report SamplePlease note: the sample below follows the structure of the online re.
PDF Draft Format for Use in Submission of Interim and Final Research
agency research, it is important for Federal agencies to manage awards in a similar fashion. The RPPR is to be used by agencies th. support research and research-related activities for use in submission of progress reports. It is intended to replace other performance reporting formats currently in use by agencie.
How to construct an optimal interim report: What the data monitoring
For each session, there is a report of interim results. The open session is attended by the sponsor and lead investigators, including the statistician(s) responsible for the trial design. These investigators are blinded to the interim treatment comparisons. The closed session is attended by the data monitoring committee members and by the ...
Progress / Interim Reports
Progress / Interim Reports. Progress reports are common in engineering. As the name suggests, they document ongoing projects. They might be one-page memos or long, formal documents. Such a report is aimed at whoever assigned the project. Its goal is to enable the manager or sponsor of a project to make informed decisions about the future of the ...
CERF interim reporting template
Fri, 10/28/2016 - 12:00. File. CERF interim reporting template.pdf 136.18 KB
Guides and Templates
NON-EXPERIMENTAL PROJECTS: Content: Interim reports should include the results for all of the analysis planned in the accepted proposal.; Format: Please use the Final Report/Working Paper template relevant to your research method (see below).; Goal: The goal is to prove that your project is progressing satisfactorily and that it can be reasonably assumed that your team will be able to prepare ...
Interim Reports
Interim Reports. You may be required to produce an interim report as part of a larger project, such as your final Individual Project. This report serves an important purpose in setting out what you are hoping to achieve and how far you have got in achieving this. The reader is looking to answer questions, such as: What is the student trying to ...
Interim Report Template
This document provides guidelines for writing an interim report for a group innovation project course. It outlines the expected content which includes a title page, abstract, table of contents, introduction, background, methodology, and conclusion. The methodology section should be divided into chapters covering project management plan, system analysis, and system design. The report should be ...
University of Lincoln Computer Science Interim Report Template
A suitable template that can be used for the interim report submission for Computer Science at the University of Lincoln. Relevant as of 2022-23. An online LaTeX editor that's easy to use.
Interim Report Research Project Report Template
Research Project - Interim Report Name Project Group Date of Submission A study on "Specify your title " Research Project submitted to Jain Online (Deemed-to-be University) In partial fulfillment of the requirements for the award of: Master of Business Administration Submitted by: Student Name USN: (Write your number) Under the guidance of:
WuXi Biologics Reports Solid 2024 Interim Results
Hong Kong, August 21, 2024 - WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 ...
Equinor Making Transition to Low Carbon Over Long Term ...
Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.

How to Write a Successful Interim Report

What is the Interim Report

How do I Create a Dissertation Interim Report?

Project Summary and Project Specifications

Updated Table of Contents

Literature Review

Current Progress

Obstacles to Progress

Planned Methodology

Future Project Timeline

Help with Writing the Dissertation Interim Report: Tips for Success

How is it Marked?

Interim reports

Advice for using this method

Expand to view all resources related to 'Interim reports'

'Interim reports' is referenced in:

Research Performance Progress Report (RPPR) - Annual, Interim, and Final

Designing the Research Proposal or Interim Report

Cite this chapter

Access this chapter

Bibliography

Author information

Rights and permissions

Copyright information

About this chapter

Download citation

Share this chapter

Save citation to file

Add to My Bibliography

How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know

Similar articles

LinkOut - more resources

Progress / Interim Reports

Search form

Guides and Templates

Grants Manual

Experimental Research intitiatives

Templates & Guides

Pre-analysis Plan

Interim Reports

Final Report and Working Paper

Dofile Templates (Experimental)

Policy engagement, outputs & dissemination

Technical Reports

Slide Presentation

Study Visit

National Policy Conference

International Conferences

Journal Publications

Institutional policies

Interim Reports

Interim report requirements

Broad and up-to-date understanding of the literature

Progress to date and next steps

Attention to detail

Relevance of literature to your project

Your interim report should:

Other University of Southampton sites

Useful Downloads

University of Lincoln Computer Science Interim Report Template

Get in touch

Press Releases

IMAGES

COMMENTS